Login
Divisions and Subsidiaries
Forest Pharmaceuticals
Forest Laboratories Europe
Cerexa, Inc.
Forest Laboratories Canada Inc.
About Forest
Overview
Forest identifies, develops, and delivers therapies that make a meaningful difference in people's lives
Products
Research
News
Investor Center
Overview
Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises
Annual Reports
Stock Information
Webcasts &
Presentations
Partnerships
Overview
Forest partners with biotech and pharmaceutical companies to develop and bring promising new medicines to market
Capabilities
Careers
Overview
Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine
Job Search
About Forest
Products
Research
News
Media Resources
Press Release Archive
All Press Releases
Business Development News
Corporate News
Financial News
Product News
R&D News
All Press Releases
06.24.2004
Forest Announces Results of Recently Completed Lexapro(R) Pediatric Depression Clinical Trial
06.24.2004
Forest Discusses Disclosure of Citalopram Clinical Trial Data in Children and Adolescents
05.06.2004
Depressed Patients Showed Improvement with Lexapro(TM) After Failure with Initial SSRI Treatment
05.06.2004
Namenda(TM) (memantine HCl) Provides Functional and Behavioral Benefits in Patients with Moderate to Severe Alzheimer's Disease
04.28.2004
New Data Highlight Positive Effect of Namenda(TM) on Brain Activity in Patients With Mild to Moderate Alzheimer's Disease
04.20.2004
Forest Laboratories Reports Earnings Per Share of $0.38 for Fiscal Fourth Quarter
04.16.2004
Forest Laboratories Receives Notification of ANDA Filing For a Generic Equivalent of Lexapro(R)
04.14.2004
Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2004 Fourth Quarter and Full Year Earnings
03.15.2004
Lexapro(R) as Effective as Paxil(R) and Well Tolerated in the Treatment of Generalized Anxiety Disorder
03.15.2004
ChemoCentryx and Forest Laboratories to Collaborate on Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics
« first
‹ previous
…
30
31
32
33
34
35
36
37
38
…
next ›
last »